Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Izaskun Ceberio"'
Autor:
Anton J. Enright, Izaskun Ceberio, Charles H. Lawrie, Marta Fernandez-Mercado, José Afonso Guerra-Assunção, Erika Larrea, Ibai Goicoechea, Jessica Okosun, Jun Wang, Ayman Gaafar, Carmen Lobo, Jude Fitzgibbon
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 8795, p 8795 (2020)
Volume 21
Issue 22
International Journal of Molecular Sciences, Vol 21, Iss 8795, p 8795 (2020)
Volume 21
Issue 22
Follicular lymphoma (FL) is a common indolent B-cell lymphoma that can transform into the more aggressive transformed FL (tFL). However, the molecular process driving this transformation is uncertain. In this work, we aimed to identify microRNA (miRN
Autor:
Molly Maloy, Juliet N. Barker, Miguel-Angel Perales, Richard J. O'Reilly, Izaskun Ceberio, James W. Young, Esperanza B. Papadopoulos, Guenther Koehne, Christina Cho, Sean M. Devlin, Sergio Giralt, Pere Barba, Patrick Hilden, Craig S. Sauter, Ann A. Jakubowski, Roni Tamari, Doris M. Ponce, Ravin Ratan, Marcel R.M. van den Brink, Hugo Castro-Malaspina
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:67-74
To evaluate the association between the hematopoietic cell transplantation-comorbidity index (HCT-CI) and the recently developed age-adjusted HCT-CI (HCT-CI/age) and transplant outcomes in the setting of CD34-selected allogeneic HCT, we analyzed a ho
Autor:
Gabriela Yurrita, Izaskun Ceberio, Jennifer Gomez, Maialen Lasa, Maria Aranzazu Aguirre, Maria Araiz, Maite Centeno, Cristina Sarasqueta, Oihane Iñarra, Camino Del Rio, Sergio Perez Martin, Nekane Sanz, Maria Rua, Beatriz Sarriegui, June Iriondo, Jesus Blanco
Publikováno v:
Blood. 136:30-31
INTRODUCTION: The use of Peripherally Inserted Central Catheters (PICCs) has increased significantly in the last years due to their advantages compared to the other types of central catheters: easier and protocolized insertion by specialized nurse-le
Autor:
Miguel-Angel Perales, Ann A. Jakubowski, Izaskun Ceberio, Brian C. Shaffer, Doris M. Ponce, Molly Maloy, Patrick Hilden, Juliet N. Barker, Roni Tamari, Sergio Giralt, Juan Montoro, Craig S. Sauter, Esperanza B. Papadopoulos, Parastoo B. Dahi, James W. Young, Guenther Koehne, Richard J. O'Reilly, Hugo Castro-Malaspina
Publikováno v:
Biol Blood Marrow Transplant
Large series of patients with acute myelogenous leukemia (AML) after ex vivo T cell-depleted (TCD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) have not been reported previously. We retrospectively analyzed the outcomes of 266 patie
Autor:
Izaskun Ceberio Echechipia, Andoni Orube Bona, Enrique Contreras Fuente, M. Jose Esnaola Aguirezabala, Sara Arévalo Lobera
Publikováno v:
International Journal of Integrated Care; Vol 18: Annual Conference Supplement 2018; 208
Cancer are more than 100 complex conditions that builds a great challenge for health care systems and proffessionals. In the last years, the reality of cancer has evolved to different situations that we must face adapting the traditionally vertical o
Autor:
Andrew M. Evens, Paul A. Carpenter, Miguel-Angel Perales, Jeffrey Schriber, Izaskun Ceberio, Peter D. Cole, Linda J. Burns, Craig H. Moskowitz, Robert T. Chen, Bipin N. Savani, Thomas C. Shea, Julie M. Vose, Nishitha Reddy, Ginna G. Laport, Uday R. Popat, Philippe Armand
Publikováno v:
Biology of Blood and Marrow Transplantation. 21:971-983
The role of hematopoietic cell transplantation (HCT) in the therapy of Hodgkin lymphoma (HL) in pediatric and adult patients is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the
Autor:
Izaskun Ceberio, Ana Jesus Gonzalez, Larraitz Arrue, Andoni Orube, Enrique Contreras, Nerea Uresandi, J. R. Furundarena, Hodei Arrizabalaga, Ana Isabel Diez, Maria Araiz, Elena Suquia
Publikováno v:
Osagaiz: osasun-zientzien aldizkaria. 1
Donostia Unibertsitate Ospitaleko hematologiako kontsultetan 2015. urtean hobekuntza-planaren diseinuan lanean hasi ginen. Konturatu ginen bertan artatzen ziren kasu askok ez ziotela baliorik eransten, ez baitzuten patologia hematologikorik. Hematolo
Autor:
Lauren Lechner, Andrew D. Zelenetz, Miguel-Angel Perales, Junting Zheng, Izaskun Ceberio, Craig S. Sauter, Jenna D. Goldberg, Hugo Castro-Malaspina, Guenther Koehne, Craig H. Moskowitz, Esperanza B. Papadopoulos, Ann A. Jakubowski, Sean M. Devlin, Sergio Giralt, Juliet N. Barker
Publikováno v:
Biology of Blood and Marrow Transplantation. 20(3):354-360
The aim of this prospective phase II trial was to determine the safety and efficacy of a nonmyeloablative conditioning program incorporating peritransplant rituximab in patients with CD20+ B cell non-Hodgkin lymphoma (B-NHL) receiving an allogeneic s
Autor:
Pere, Barba, Ravin, Ratan, Christina, Cho, Izaskun, Ceberio, Patrick, Hilden, Sean M, Devlin, Molly A, Maloy, Juliet N, Barker, Hugo, Castro-Malaspina, Ann A, Jakubowski, Guenther, Koehne, Esperanza B, Papadopoulos, Doris M, Ponce, Craig, Sauter, Roni, Tamari, Marcel R M, van den Brink, James W, Young, Richard J, O'Reilly, Sergio A, Giralt, Miguel-Angel, Perales
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 23(1)
To evaluate the association between the hematopoietic cell transplantation-comorbidity index (HCT-CI) and the recently developed age-adjusted HCT-CI (HCT-CI/age) and transplant outcomes in the setting of CD34-selected allogeneic HCT, we analyzed a ho
Autor:
Antonia Rodriguez Izquierdo, Samuel Romero, Eduardo Ríos Herranz, Cristina Barrenetxea Lekue, Izaskun Ceberio, Luis Palomera, Antonio Gutierrez, Inmaculada Heras, R. Alonso, Joan Buch, Irene Garcia-Garcia, Joan Bargay, Narvaez Javier, Cecilia Carpio, Ramón García-Sanz, Manuel Espeso de Haro, Carmen Martinez
Publikováno v:
Blood. 132:2936-2936
Background: Nivolumab, an immune checkpoint inhibitor, has been tested in patients with classical Hodgkin lymphoma (cHL) who failed standard treatment options and has demonstrated remarkable activity with acceptable safety profile in clinical trials.